Becton Dickinsonvs.ResMed
BDX vs RMD · both in Medtech & devices, part of the Medicine, pharma & life science value chain: Medical equipment and devices, from surgery and cardiology to robotics.
Becton Dickinson is about 1.5× larger than ResMed by market cap; ResMed trades at the lower P/E (21.1 vs 52.7); year to date, Becton Dickinson leads (+19.8% vs −5.9%).
Side by side
| BDX | RMD | |
|---|---|---|
| Market cap | $49.7B | $32.1B |
| Price | $183.75 | $230.05 |
| Today | +0.5% | +1.5% |
| Return YTD | +19.8% | −5.9% |
| Return 1Y | +19.9% | −19.7% |
| Since June 26, 2026 | +17.8% | +14.9% |
| P/E | 52.7 | 21.1 |
| P/S | 2.4 | 5.7 |
| P/B | 2.0 | 4.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Becton DickinsonBDX
Syringes and needles sit at the recognisable end of the range. Becton Dickinson's portfolio is broad, spanning medical consumables alongside diagnostic systems and drug delivery equipment.
Full BDX profile →ResMedRMD
CPAP machines and masks for sleep apnea, sold with cloud software, next to a wider respiratory equipment range.
Full RMD profile →More BDX & RMD comparisons
Other head-to-heads in the Medtech & devices segment.